Supplementary Figure 9 from CD44posCD49fhiCD133/2hi Defines Xenograft-Initiating Cells in Estrogen Receptor–Negative Breast Cancer

Meyer, Matthew J.; Fleming, Jodie M.; Lin, Amy F.; Hussnain, S. Amal; Ginsburg, Erika; Vonderhaar, Barbara K.

doi:10.1158/0008-5472.22383354.v1

Supplementary Figure 9 from CD44^posCD49f^hiCD133/2^hi Defines Xenograft-Initiating Cells in Estrogen Receptor–Negative Breast Cancer

journal contribution

posted on 2023-03-30, 19:32 authored by Matthew J. Meyer, Jodie M. Fleming, Amy F. Lin, S. Amal Hussnain, Erika Ginsburg, Barbara K. Vonderhaar

Supplementary Figure 9 from CD44^posCD49f^hiCD133/2^hi Defines Xenograft-Initiating Cells in Estrogen Receptor–Negative Breast Cancer

History

ARTICLE ABSTRACT

Defining the populations of tumor-initating cells that are present in tumors is a first step in developing therapeutics to target these cells. We show here that both CD44posCD24neg and CD44posCD24pos cell populations in estrogen receptor (ER) α–negative breast tumors are tumorigenic in murine xenograft models. We also describe a third population of xenograft-initiating cells (XIC) enriched in CD44posCD49fhiCD133/2hi cells that display heightened tumorigenicity, self-renewal in vivo, and the capacity to give rise to functional and molecular heterogeneity. Consistent with their capacity for self-renewal, these cells express elevated levels of Sox2, Bmi-1, and/or Nanog and their CpG islands are hypermethylated relative to nontumorigenic cells. These differences in methylome regulation may be responsible for the dramatic functional differences between the two populations. The identification of CD44posCD49fhiCD133/2hi XIC in ER-negative tumors may lead to expanded understanding of these tumors and ultimately the development of therapeutics designed to specifically target the cells. Cancer Res; 70(11); 4624–33. ©2010 AACR.